— Know what they know.
Not Investment Advice

VSMD OTC

Vasamed, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -90.0% 5Y: -99.2%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Instruments & Supplies · Tech Score Neutral · Power 49 · $802 mcap · 8M float · 0.0008% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000001-0.0001
Volume66
Avg Volume62
Beta-1.01
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOPaulita LaPlante
Employees5
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date1996-02-14
7615 Golden Triangle Drive
Eden Prairie, MN 55344
US
952-944-5857
About Vasamed, Inc.

Vasamed, Inc. specializes in the development, manufacturing, licensing, and distribution of a comprehensive suite of products, software solutions, and services focused on the assessment and management of circulatory health throughout the United States. Key among its offerings is the SensiLase PAD-IQ, a device designed to measure skin perfusion pressure, conduct pulse volume recordings, and calculate the Ankle-Brachial Index utilizing Doppler-derived pressure readings. The company also provides advanced Wound Imaging & SmartDraw systems for precise wound measurement. Additionally, Vasamed offers the PAD-IQ Studycast, a platform that facilitates the rapid and secure transmission of diagnostic test results to vascular specialists. This enables prompt interpretation of findings and supports timely, medically indicated therapeutic interventions. For safeguarding its equipment, the company also supplies a custom carrying case for the PAD-IQ system. Vasamed caters to both clinicians and patients, and has been operating since its founding in 1988. Its corporate headquarters are located in Eden Prairie, Minnesota.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms